Thrombus formafigtion plays a significant role in disease of saphenous vein bypass grafts. Use of oral anticoagulants has not been tested in treatment of thrombotic occlusion of saphenous vein graft (SVG) disease. Here we describe the use of the novel oral anticoagulant rivaroxaban in the treatment of occlusive SVG disease with intraluminal thrombus, leading to successful recanalization.
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Rivaroxaban is a new oral anticoagulant, a direct factor Xa inhibitor which is currently FDA approved for the prevention and treatment of venous thromboembolism, and for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation. 1 ATLAS ACS 2-TIMI 51 demonstrated reduced risk of the composite end point of death from cardiovascular causes, myocardial infarction, or stroke in patients with a recent acute coronary syndrome placed on rivaroxaban at the expense of increased risk of non-fatal major bleeding and intracranial hemorrhage. 2 Thrombosis, intimal hyperplasia and atherosclerosis are the common mechanisms of SVG disease and occlusion; however, the Post CABG trial failed to demonstrate higher SVG primary patency rates with low-dose anticoagulation with warfarin as a primary prevention strategy. 3 This case highlights the potential benefit of the new-generation oral anticoagulants in the secondary prevention and treatment of saphenous vein thrombosis-related disease. A similar approach was reported by Fiorina et al. in a small case series of 14 patients with non-ST-elevation myocardial infarction and occluded SVGs, in which after angioplasty with an undersized balloon to achieve TIMI flow 1-2, patients were placed on anticoagulation with warfarin for 11±7 days. A follow-up angiogram revealed that all the SVGs were patent, 14% of them with no residual lesions. 4
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